
    
      Transplant patients participating in this clinical trial will receive one of 3 standard
      pre-transplant chemotherapy preparative regimens as appropriate for their specific disease.
      They will then receive a standard non-manipulated donor stem cell infusion on transplant day
      (day 0) followed by cyclophosphamide (days +3 and +4) and an alpha-beta t-cell reduced donor
      stem cell infusion on day +7.
    
  